Drug Pricing

Drug Pricing

Wayne Winegarden Discusses Drug Price Controls on Lars Larson Show

Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent Forbes op-ed on prescription drug price controls and how they would threaten access to innovative cures for America’s patients on “The Lars Larson Show.”
Commentary

We Need A Cure For The Arrogance Of Drug Price Control Advocates

“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Commentary

The Senate’s New Drug Bill Is Socialism Lite

House Speaker Nancy Pelosi has a radical new plan to let the federal government set drug prices. In the hopes of combating this bill, many Republicans are holding up Senator Chuck Grassley’s Prescription Drug Pricing Reduction Act as a more moderate alternative. That’s a mistake. While Grassley’s bill isn’t as ...
Drug Innovation

Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show

Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Drug Pricing

Henry Miller explains how the market can lower drug prices on the Lars Larson Show

Henry Miller joined the nationally syndicated Lars Larson Show to discuss how the market can lower drug prices. Henry Miller’s interview starts at the 46 minute mark.
Commentary

Trump’s drug price controls could cost lives

The Trump administration is preparing a proposal that will likely peg what Medicare pays for prescription drugs to prices in other nations. Name brand drugs generally cost less abroad because foreign governments forcibly control their prices. So this international price index would effectively import those foreign price controls. That may sound like a ...
Drug Pricing

What to Know in Washington: When Drugs Make News, Trump Reacts

Staffers at the Department of Health and Human Services have gotten used to a pattern: President Donald Trump sees a news report on spikes in prescription-drug list prices, Secretary Alex Azar is called to a meeting in the Oval Office, and a policy in the discussion stage gets accelerated and ...
Commentary

Let’s Let Market Forces Lower Drug Prices

The Trump Administration on July 31 announced steps that could lead to the importation of prescription drugs from Canada, where prices are lower. This strategy is favored by President Trump but has long been opposed by many Republicans. Health and Human Services Secretary Alex Azar said that the policy would enable Americans ...
Commentary

Louisiana Tries Hard, But Federal Obstacles Cause Hepatitis C Plan To Fall Short

A state and a biopharmaceutical company agreed recently on a new way to pay for treating patients with Hepatitis C, the most deadly infectious disease in America. At a time when politicians and drug companies are squabbling over drug prices, the deal between Louisiana and Asegua, a subsidiary of Gilead Sciences, ...
Commentary

Trump’s Drug Importation Policy Is Folly, Just Ask Canadians

The Trump Administration’s Department of Health and Human Services (HHS) has officially proposed legalizing the importation of drugs from Canada (e.g. the Safe Importation Action Plan). Canadians’ reactions provide an important perspective demonstrating why drug importation will harm the U.S. Despite assurances from Prime Minister Justin Trudeau, Canadians are worried ...
Drug Pricing

Wayne Winegarden Discusses Drug Price Controls on Lars Larson Show

Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent Forbes op-ed on prescription drug price controls and how they would threaten access to innovative cures for America’s patients on “The Lars Larson Show.”
Commentary

We Need A Cure For The Arrogance Of Drug Price Control Advocates

“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Commentary

The Senate’s New Drug Bill Is Socialism Lite

House Speaker Nancy Pelosi has a radical new plan to let the federal government set drug prices. In the hopes of combating this bill, many Republicans are holding up Senator Chuck Grassley’s Prescription Drug Pricing Reduction Act as a more moderate alternative. That’s a mistake. While Grassley’s bill isn’t as ...
Drug Innovation

Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show

Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Drug Pricing

Henry Miller explains how the market can lower drug prices on the Lars Larson Show

Henry Miller joined the nationally syndicated Lars Larson Show to discuss how the market can lower drug prices. Henry Miller’s interview starts at the 46 minute mark.
Commentary

Trump’s drug price controls could cost lives

The Trump administration is preparing a proposal that will likely peg what Medicare pays for prescription drugs to prices in other nations. Name brand drugs generally cost less abroad because foreign governments forcibly control their prices. So this international price index would effectively import those foreign price controls. That may sound like a ...
Drug Pricing

What to Know in Washington: When Drugs Make News, Trump Reacts

Staffers at the Department of Health and Human Services have gotten used to a pattern: President Donald Trump sees a news report on spikes in prescription-drug list prices, Secretary Alex Azar is called to a meeting in the Oval Office, and a policy in the discussion stage gets accelerated and ...
Commentary

Let’s Let Market Forces Lower Drug Prices

The Trump Administration on July 31 announced steps that could lead to the importation of prescription drugs from Canada, where prices are lower. This strategy is favored by President Trump but has long been opposed by many Republicans. Health and Human Services Secretary Alex Azar said that the policy would enable Americans ...
Commentary

Louisiana Tries Hard, But Federal Obstacles Cause Hepatitis C Plan To Fall Short

A state and a biopharmaceutical company agreed recently on a new way to pay for treating patients with Hepatitis C, the most deadly infectious disease in America. At a time when politicians and drug companies are squabbling over drug prices, the deal between Louisiana and Asegua, a subsidiary of Gilead Sciences, ...
Commentary

Trump’s Drug Importation Policy Is Folly, Just Ask Canadians

The Trump Administration’s Department of Health and Human Services (HHS) has officially proposed legalizing the importation of drugs from Canada (e.g. the Safe Importation Action Plan). Canadians’ reactions provide an important perspective demonstrating why drug importation will harm the U.S. Despite assurances from Prime Minister Justin Trudeau, Canadians are worried ...
Scroll to Top